{"id":2190,"date":"2019-10-02T14:29:08","date_gmt":"2019-10-02T12:29:08","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2190"},"modified":"2024-04-11T10:39:51","modified_gmt":"2024-04-11T08:39:51","slug":"stem-cells-and-neurodegenerative-diseases","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/neuroscience-area\/neuroscience-program\/stem-cells-and-neurodegenerative-diseases\/","title":{"rendered":"Stem cells and Neurodegenerative diseases"},"content":{"rendered":"\n

\n\t\tStem cells and Neurodegenerative diseases\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

Our research interests lie primarily in the area of stem cells and regenerative medicine. Overall, our research goal is to leverage emerging stem cell technologies to better understand neurodegenerative disease, such as PD as well as neurodevelopmental disease such as THD, and to develop novel tools for the discovery of disease mechanisms and treatments. Over the past 10 years, in close collaboration with the group of Dr. Angel Raya and Dr. Eduardo Tolosa, we have amassed a large collection of iPSC lines representing patients of Parkinson’s disease (PD), including idiopathic and genetic forms associated to LRRK2G2019S mutation, as well as asymptomatic LRRK2G2019S carrier relatives and healthy individuals. For most of the LRRK2G2019S patients and carriers, her lab has also generated isogenic gene-edited iPSC controls. These iPSC lines have been used to generate dopaminergic neurons that display phenotypic hallmarks of PD and recapitulate the cellular, molecular, and epigenetic alterations found in neurons from PD patients. Moreover, leveraging on the advantages of iPSC-based disease modeling technology, we have recently unveiled the pathogenic contribution of non-neuronal cells to dopaminergic neurodegeneration in PD, uncovered early functional alterations in PD iPSC-derived neuronal networks, and screened for small molecules preventing neurodegeneration in PD. We also adopt gene editing approaches in our iPSC models to determine how specific targets influence protein aggregation and neuronal pathophysiology and to reveal mechanisms by which new protective genetic variants impact disease onset and progression. Recently, we are also developing advanced experimental in vitro models, such as brain-like organoids, to recapitulate the complexity of the human brain.<\/p>\n

135<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"Stem-cells-and-Neurodegenerative-diseases\"\n\t\t\t\t\tStrategic Lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tFocusing on disease modeling of neurodegeneration using hiPSCs
\nModelling neurodevelopmental diseases with 3D brain organoids
\nIdentify new molecular targets for potential therapeutic options
\nInvestigate the role of the genetic makeup of PD patients who carry pathogenic mutations in the development of PD-related neurodegeneration
\nInterested in understanding the molecular and cellular contributions of the neuro-immune system in Parkinson’s disease.
\nDeveloping a human neural platform for assaying antigen-antibody interactions for Autoimmune Encephalitis\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

– Baldeschi AC, Zattoni M, Vanni S, Nikolic L, Ferracin C, La Sala G, Summa M, Bertorelli R, Bertozzi SM, Giachin G, Carloni P, Bolognesi ML, De Vivo M, Legname G. Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance<\/strong>. J. Med. Chem. 2022;65(13):8998-9010. doi:10.1021\/acs.jmedchem.2c00205.<\/p>\n

– Pons Espinal M, Blasco Agell L, Consiglio A. Dissecting the non-neuronal cell contribution to Parkinson’s disease pathogenesis using induced pluripotent stem cells<\/strong>. Cell. Mol. Life Sci. 2021;78(5):2081-2094. doi:10.1007\/s00018-020-03700-x.<\/p>\n

– Carola G, Malagarriga D, Calatayud C, Pons Espinal M, Blasco Agell L, Richaud Patin Y, Fernandez Carasa I, Baruffi V, Beltramone S, Molina E, Dell’Era P, Toledo Aral JJ, Tolosa E, Muotri AR, Ojalvo JG, Soriano J, Raya A, Consiglio A. Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration<\/strong>. NPJ Parkinsons Dis. 2021;7(1):55-55. doi:10.1038\/s41531-021-00198-3.<\/p>\n

– Ferrer Lorente R, Lozano Cruz T, Fern\u00e1ndez Carasa I, Milowska K, de la Mata FJ, Bryszewska M, Consiglio A, Ortega P, G\u00f3mez R, Raya A. Cationic Carbosilane Dendrimers Prevent Abnormal a-Synuclein Accumulation in Parkinson’s Disease Patient-Specific Dopamine Neurons<\/strong>. Biomacromolecules. 2021;22(11):4582-4591. doi:10.1021\/acs.biomac.1c00884.<\/p>\n

– Klionsky DJ, Abdel Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, [+2898 authors], Oshima S, Rong YG, Sluimer JC, Stallings CL, Tong CK. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).<\/strong> Autophagy. 2021;17(1):1-382. doi:10.1080\/15548627.2020.1797280.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t– 21CEE001. A Human Neural Platform for Assaying Antigen-Antibody Interactions for<\/strong>
\nAutoimmune Encephalitis.<\/strong> COMISSI\u00d3 EUROPEA. Budget: 150000. 2021-2023. PI: CONSIGLIO, ANTONELLA.”
\n– LCX21001 . Characterization at the single-cell level of the neuronal response to neuroinflammatory signaling using an in-vitro co-culture system in the context of Parkinson’s disease.<\/strong> FUNDACI\u00d3 “LA CAIXA” . Budget: 115092. 2021-2024. PI: CONSIGLIO, ANTONELLA.
\n– 21MAR008. Developing patient-tailored therapeutic candidates for rare genetic forms of pediatric parkinsonism.<\/strong> Fundaci\u00f3 La Marat\u00f3 de TV3. Budget: 102000. 2021-2024. PI: CONSIGLIO, ANTONELLA.
\n– PNJ21011 . Colchine to prevent a-synuclein accumulation<\/strong>. INDENA S.L. . Budget: 40000. 2021-. PI: CONSIGLIO, ANTONELLA.
\n– 20PSJ028. NeurAntigenv2: A Human Neural Platform for Assaying Antigen- Antibody Interactions for Autoimmune Encephalitis<\/strong>. FUND.INST.CENTRES RECER.CATALALUYA. Budget: 10000. 2020-2022. PI: CONSIGLIO, ANTONELLA.\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT083: EP 23383041.3
\nIP: Antonella Consiglio
\nNEW METHODS FOR THE DETECTION OF NEURONAL ANTIBODIES\n\t\t\t\t\tMore information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

In 2019, togheter with Dr. Raya, Antonella Consiglio received the “City of Barcelona Award” to the life sciences.<\/p>\n2021:
\n– ICREA Academy Award. 1 Jan 2020 – 31 Dec 2024; PI: Antonella Consiglio
\n– Premio de investigaci\u00f3n Merck: “”Terapia g\u00e9nica con c\u00e9lulas madre derivadas de tejido adiposo para la obesidad y enfermedades metab\u00f3licas asociadas”. PI: Laura Herrero Colaboradores: Antonella Consiglio (IDIBELL-IBUB) y N\u00faria Casals (UIC)\n\t\t\t\t\"Antonella-Consiglio22\"\n

\n\t\tConsiglio, Antonella\n\t<\/h4>\n

\n\t\t\n\t\taconsiglio@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Antonella-Consiglio22\"\n

\n\t\tConsiglio, Antonella\n\t<\/h4>\n

\n\t\t\n\t\taconsiglio@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\t@ConsiglioLab\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup Leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tStudents\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup Leaders\n\t\t\t\t\t\t\t\t\t\t\t